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Abstract
Introduction: Hepatitis C virus (HCV) infection can lead to severe liver disease. Pregnant women are already routinely
screened for several infectious diseases, but not yet for HCV infection. Here we examine whether adding HCV screening to
routine screening is cost-effective.
Methods: To estimate the cost-effectiveness of implementing HCV screening of all pregnant women and HCV screening of
first-generation non-Western pregnant women as compared to no screening, we developed a Markov model. For the
parameters of the model, we used prevalence data from pregnant women retrospectively tested for HCV in Amsterdam, the
Netherlands, and from literature sources. In addition, we estimated the effect of possible treatment improvement in the
future.
Results: The incremental costs per woman screened was J41 and 0.0008 life-years were gained. The incremental cost-
effectiveness ratio (ICER) was J52,473 which is above the cost-effectiveness threshold of J50,000. For screening first-
generation non-Western migrants, the ICER was J47,113. Best-case analysis for both scenarios showed ICERs of respectively
J19,505 and J17,533. We estimated that if costs per treatment were to decline to J3,750 (a reduction in price of J31,000),
screening all pregnant women would be cost-effective.
Conclusions: Currently, adding HCV screening to the already existing screening program for pregnant women is not cost-
effective for women in general. However, adding HCV screening for first-generation non-Western women shows a modest
cost-effective outcome. Yet, best case analysis shows potentials for an ICER below J20,000 per life-year gained. Treatment
options will improve further in the coming years, enhancing cost-effectiveness even more.
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Introduction
Hepatitis C virus (HCV) is primarily a blood-borne virus and
causes persistent viremia in about 75% of those infected [1]. Over
the course of decades, chronic HCV infection can lead to liver
cirrhosis and, eventually, death. HCV infection is an asymptom-
atic disease and as such, treatment is mostly initiated in an
advanced stage of disease [1].
In high-income countries, health-care associated HCV trans-
mission was effectively halted by the introduction of donor blood
screening in 1991. As a result, the vast majority of new HCV
infections occur among specific risk groups, in particular injecting
drug users (IDUs) through sharing of injection equipment [2]. In
contrast, in low- and middle-income countries, the majority of
HCV transmissions remains health-care associated primarily due
to inadequately sterilized syringes and medical equipment [1].
In the Netherlands, HCV prevalence is estimated at 0.22%
(min: 0.07% max: 0.37%) [3]. Blood donors and HIV positives are
routinely screened for HCV, but there is no universal screening
policy for HCV that targets the general population. In the past
decade, several national and regional HCV (pilot) screening
campaigns have been conducted in the Netherlands for specific
risk groups, such as active drug users participating in harm-
reduction programmes [4,5] as well as others hidden in the general
population (e.g. those who have had a blood transfusion or
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injected drugs one time in the remote past). The latter campaign
only ran for limited periods of time [4,6].
A recent study in the Netherlands showed HCV prevalence
among indigenous pregnant women of 0.26% (95% CI: 0.15–
0.46), which is similar to the prevalence in the general population
[7]. However, the prevalence was somewhat higher among first-
generation migrants from non-Western countries (0.70%; 95% CI:
0.43–1.29) [7]. The transmission rate from mother to child is
estimated to be around 5% in HIV-negative mothers, depending
on the viral RNA load of the mother [8].
Currently, HCV-infected patients are treated with a weekly
pegylated interferon injection plus a daily oral dose of ribavirin.
Genotypes 1 and 4 are more difficult to treat than genotypes 2 and
3. Two protease inhibitors (boceprevir and telaprevir) have been
recently licensed for treatment of HCV infection with genotype 1
in the Netherlands. Although these new treatment options are
more expensive, when added to pegylated interferon and ribavirin,
the response rate improves substantially [9,10]. With even more
effective treatment to be expected, it becomes increasingly
important to identify undiagnosed HCV-infected individuals.
Identifying HCV-infected individuals can lighten the future
burden of disease and help prevent secondary transmission.
HCV screening programmes in populations with low HCV
prevalence and standard treatment are mostly not cost-effective
[4,11,12]. The reasons for this are the relatively low prevalence
and treatment outcome, screening setting and discount rate and
the willingness –to -pay of the public, which depends on several
economic, social and political factors [11]. Yet, HCV screening in
settings where screening for other infectious diseases already exists
might be cost-effective. In the Netherlands, as in many other
countries, pregnant women are regularly screened in the third
month of pregnancy for several infectious diseases, including
hepatitis B virus (HBV) and HIV [13]. Therefore, adding HCV
testing to this screening procedure will only require a minor
adjustment, limited investment, and low costs. Both the HCV-
infected mother and her child would benefit from prenatal
screening, because treatment can start relatively early in the course
of infection and thus avert serious HCV-related complications. To
examine whether adding HCV testing to routine screening for
pregnant women is cost-effective, we developed a Markov model,
taking the benefits for the mother into account. We used HCV-
prevalence data among pregnant women collected in 2003,
including ethnicity. Scenario studies were done to estimate
whether implementation of HCV screening for all pregnant
women was cost-effective and whether it was cost-effective to
screen only first-generation non-Western women. In addition,
cost-effectiveness of various treatment scenarios was explored.
Methods
Ethics statement
The medical ethics committee of the Academic Medical Centre
(MEC AMC) approved the current study.
In this analysis, we express cost-effectiveness as the ratio of the
net expenditures and net health outcomes. The net expenditures
reflect the difference in costs between a situation where screening
is conducted and a situation where there is no routine screening,
reflecting current practice. Screening is deemed cost-saving if costs
in the screening scenario are lower than current practice where no
screening is conducted. If net expenditures are positive, sufficient
positive health gains are needed to make the screening cost-
effective. In the Netherlands, screening is certainly deemed to be
cost-effective if the cost per life-year gained (LYG) is #J20,000,
and potentially still cost-effective up to J50,000 per LYG [14].




where C are the costs and LY are life-years in the scenario with
screening (s) and without screening (ns), respectively. The net costs
and net LYG are calculated as the difference in total costs and LYG
with and without screening. Each year a woman is alive in the
Markov model (see Figure 1) is counted as a life-year, independent
of the transition state she is in. This analysis is conducted from a
health care perspective, only accounting for direct medical costs.
We expressed all costs in 2011 price levels and discounted them
at an annual rate of 4%. Life-years were discounted at an annual
rate of 1.5%, according to Dutch guidelines [8]. The model was
built using Microsoft Excel 2007.
Markov model
We developed a Markov model to compare current practice (no
routine HCV screening) with HCV screening of women during
pregnancy and subsequent treatment (scenario 1). We assumed
that women who receive no routine HCV screening will be
screened by a GP when developing symptoms in a later stage of
chronic infection. Women were eligible to enter the model at
pregnancy at 31 years of age and for first-generation non-Western
women at 29 years of age, approximating the average age of first
pregnancy in the Amsterdam region [15]. Women at entrance did
not have HCV symptoms and were HIV-negative, because we
assumed that indeed otherwise they would have been diagnosed
already. It was assumed that 42% of the anti-HCV positive women
had already cleared the infection spontaneously [16]. In the
model, these women were considered HCV-negative.
In the current practice scenario (scenario 1), women were either
HCV negative or HCV asymptomatic at model entrance. From the
HCV-asymptomatic stage, they moved through the different
optional HCV health stages (e.g., symptomatic infection, cirrhosis,
decompensated cirrhosis, hepatocellular carcinoma (HCC), and
liver transplantation) (Figure 1A), according to annual transition
probabilities given in Table 1. Once diagnosed with HCV during
pregnancy, we assumed that 50% of the diagnosed women received
treatment in the second year after diagnosis. In this scenario,
treatment consisted of peginterferon alfa and ribavirine for genotype
2–4 with added protease inhibitors for genotype 1. We refer to this
as ‘new treatment regimen’. It was assumed that cirrhosis does not
develop during HCV therapy. If therapy was not successful, women
remained chronically infected and return to the (a)symptomatic
stage. After liver transplantation, women moved to the ‘after
transplantation’ state until death. The model included two types of
mortality: competing mortality (due to causes unrelated to HCV)
and HCV-related mortality (through decompensated cirrhosis,
hepatocellular carcinoma [HCC] or liver transplantation). The
probabilities of competing deaths and liver cirrhosis were age-
dependent. In this scenario (scenario 1), we assumed that
asymptomatic infections were not diagnosed; there were no costs
related to this health stage and there was no treatment possibility.
Medical costs were counted for all symptomatic HCV stages.
In the base-case analysis (scenario 1a), women entered the
model and were screened for HCV. Women moved to either the
HCV-negative or the chronic-HCV infection state. It was assumed
that women who were screened and diagnosed were chronically
infected with HCV, and thus HCV progression was modelled as in
the current practice scenario (Figure 1B). Treatment was
administered according to the new treatment regimen.
Cost Effectiveness of Antenatal HCV Screening
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The same situation was estimated for only first-generation non-
Western pregnant women (scenario 1b), because non-Western
countries in general have a higher HCV prevalence [7]. Western
was defined as Western Europe (excluding Portugal, Spain, and
Italy because of higher HCV rates), Australia, New Zealand, and
North America; all other countries were categorized as non-
Western. Ethnicity was determined by the country of birth of the
woman’s mother. If the mother was native Dutch, ethnicity was
determined by the birth country of the participant’s father.
In scenario 2a (screening all women) and scenario 2b (screening
only first-generation non-Western women), all women diagnosed
with HCV were treated with peginterferon alfa and ribavirine, the
standard of care regimen. In scenarios 3a (screening all women)
and scenario 3b (screening only first generation non-Western
women), we used a hypothetical future treatment regimen where
the new protease inhibitors were added to the standard of care
treatment for all genotypes.
Analysis
To account for uncertainty, beta distributions were used for the
transition-probability parameters [17]. All variables, including
distributions and ranges are summarized in Table 1. We
performed 10,000 simulations. For every run, a set of parameters
was sampled from the parameter space. For parameters where the
95% confidence interval was not available, a range of 20% around
the point estimate was used as the standard deviation. For the cost
parameters, the standard deviation was assumed to be as high as
the mean cost [17], assuming a gamma distribution.
One-way sensitivity analysis
A sensitivity analysis was performed to examine the contribution
of the various parameters to variation in ICERs, represented in a
tornado diagram. To obtain the respective ranges each parameter
was increased or reduced once a time with 25%.
In addition, we performed a best-cases analysis for both
scenarios, with all parameters in the model plus or minus 25%
to optimize cost-effectiveness. Finally, we estimated to what extent
treatment costs should decline in order for HCV screening to
conform to a cost-effective threshold of J20,000.
Epidemiological aspects
We used data from the 2003 routine screening, in which all
pregnant women in their 10th to12th week of pregnancy were
routinely tested for hepatitis B, syphilis and HIV at the local
antenatal clinics in the Amsterdam area. The screening from 2003
was chosen for retrospective HCV testing because ethnicity data
Figure 1. Schematic description of the Markov model. Annually, women move between health stages according to defined transition rates
given in Table 1. The natural history of HCV infection (hepatitis C virus) is modelled through the stages of chronic infection, cirrhosis, decompensated
cirrhosis, hepatocellular carcinoma (HCC), liver transplantation, and the years after transplantation. The dotted arrows indicate competing mortality.
In Figure 1A the model is presented for the women who are not routinely screened for HCV during their pregnancy and are diagnosed in a later stage
of infection, in Figure 1b the model is presented for women who are routinely screened during their pregnancy.
doi:10.1371/journal.pone.0070319.g001
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Table 1. Overview of annual transition probabilities and cost variables used in the Markov model.
Variable Value Distribution/range Reference
Probability of HCV infection, all women 0.002# Beta (9, 4555) [15]
Probability of HCV infection, first generation non-Western migrants 0.0043# Beta (7, 1605) [15]
Transition from asymptomatic to symptomatic HCV 0.012 [4]
Percentage genotype 1* 24% [15]
Percentage genotype 2 22%
Percentage genotype 3 30%
Percentage genotype 4 24%
Transition from chronic disease to treatment 0.50 [4,25]
Probability of successful treatment outcome:
Scenario 1 (new protease inhibitors)**
Genotype 1 0.70 [26]
Genotype 2 and 3 0.78 [27]
Genotype 4 0.56 [27]
Scenario 2 (standard of care)
Genotype 1 0.40
Genotype 2 and 3 0.78
Genotype 4 0.56
Scenario 3 (possible future regimen)
Genotype 1 0.78
Genotype 2 and 3 0.78
Genotype 4 0.78
Transition to cirrhosis per year
$ Range: [18]
20–39 years 0.000 0.00–0.001
40–49 years 0.001 0.00–0.002
50–59 years 0.004 0.003–0.005
60–69 years 0.005 0.003–0.007
.70 years 0.019 0.015–0.02
Transition from cirrhosis to decompensated cirrhosis 0.039 Beta: (14.617, 260.1732) [27]
Transition from cirrhosis to HCC 0.015 [12]
Transition from decompensated cirrhosis to HCC 0.015 [12]
Transition from decompensated cirrhosis to liver transplantation 0.031 [12]
Transition from decompensated cirrhosis to HCV related death 0.129 [12]
Transition from HCC to liver transplantation 0.031 [12]
Transition from HCC to HCV-related death 0.43 Beta (117.1–155.23) [27]
Transition from post transplantation to HCV-related death 0.21 Beta (430, 1617). [12,28]
Transition after transplantation to HCV-related death 0.057 Beta (112, 2027) [12,28]
Competing mortality Depending on age [29]
Costs
Cost, antibody HCV test J12.69 Based on PHSA Laboratory prices
Cost, RNA-test J122.11 Based on PHSA Laboratory prices
Cost, chronic infection, per year J158.73 Range: J79.37–J317.46 [23]
Cost treatment
Scenario 1 (new protease inhibitors)**
Genotype 1 (24 w) J34,900 (Mean cost for Boceprevir
and telaprevir)
[30]
Genotype 2/3 J9830 [31]
Genotype 4 J16,178 [31]
Scenario 2 (standard of care)
Genotype 1 J16,178
Cost Effectiveness of Antenatal HCV Screening
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were collected. Annually, 10,000 to 213,000 women are tested.
Further details on this dataset are described elsewhere [13,15]. As
noted, women were tested retrospectively by means of an HCV-
antibody test, and positive test results were confirmed with an
immunoblot. Positive antibody test results were then tested for
HCV RNA and genotyped.
Costing aspects
The costs for the different health states were derived from the
literature and indexed to 2011 prices (Table 1). Our analysis
included the cost of HCV screening, medication (including
pharmacists’ fees), diagnostic tests, costs for liver transplantation,
as well as for decompensated cirrhosis and HCC.
Results
Base-case analysis
The incremental cost per woman screened was J41, and 0.0008
life-years were gained in the scenario in which all pregnant women
were screened, resulting in an ICER of J52,473. For screening
only first-generation non-Western women, the ICER was J47,113
(see Table 2). Screening only pregnant women that migrated from
non-Western countries was more cost-effective than screening all
pregnant women. In both scenarios, the ICER was above the
certain cost-effectiveness threshold of J20,000, but the ICER for
first-generation non-Western migrants was under the J50,000
threshold and therefore moderately cost-effective.
Best-case scenario
Table 3 shows the results of the best-case scenarios. When
screening all women or only first generation non-Western
pregnant migrants, the ICER in the best-case scenario is below
the potential cost-effectiveness threshold of J20,000, with
J19,505 for all pregnant women and J17,533 for first-generation
non-Western women.
We estimated that if treatment costs decline to J3,750,
screening pregnant women will be cost-effective at a threshold of
J20,000. A decline of treatment costs to J6,750 for first
generation non-Western women will also be cost-effective.
Table 2. Cost-effectiveness outcomes for all pregnant women and first-generation non-Western women (scenarios 1a and 1b),
based on probabilistic uncertainty analysis (10000 simulations).
Mean costs Mean life years Incremental costs LYG ICER (J/LYG)
All pregnant women Screening J 55,474 35492.8 J 41,869 0,80 J 52,473
No routine screening J13,605 35492.0
non-Western
migrants
Screening J106,307 36378.6 J 77,582 1,65 J 47,113
No routine screening J 28,725 36377.0
The incremental cost-effectiveness ratio (ICER) is calculated with reference to the ‘‘no routine screening’’ strategy.
LYG:life years gained.
ICER: incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0070319.t002
Table 1. Cont.
Variable Value Distribution/range Reference
Genotype 2/3 J9,830
Genotype 4 J16,178




Annual cost cirrhosis J821.73 Range min - max: J410.87–J
1,643.47
[23]
Cost decompensated cirrhosis, per year J27,921.72 [32]
Cost HCC, per year J21,054.92 Range: J10,527.46–J42,109.85 [23]
Cost liver transplantation J143,226.96 Range: J71,613.48–J286,453.93 [23]
Cost after transplantation, per year J20,714.27 Range: J10,357.13–J41,428.53 [23]
HCV: hepatitis C virus.
HCC: hepatocellular carcinoma.
#In the prevalence a clearance rate of 42% [14] was included. The prevalence used in the model for all pregnant women is 0.2% (9/4563; 95% CI: 0.10–0.37) and for first
generation non-Western women 0.43% (7/1612; 95% CI 0.21–0.89).
$
Transition rate is age-dependent.
*same distribution was used for first-generation non-Western women.
**new protease inhibitors are added to the standard of care regimen (peginterferon alfa and ribavirine).
doi:10.1371/journal.pone.0070319.t001
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Treatment scenarios
We examined a scenario in which standard of care treatment
was given to all women infected with genotypes 1–4 (scenarios 2a
and 2b). In both scenarios, adding HCV screening to an already
existing routine screening program was probably cost-effective.
Screening all pregnant women resulted in an ICER of J44,952,
and screening only first-generation non-Western women resulted
in an ICER of J38,861. Best-case scenarios revealed ICERs of
J16,313 and J14,153, respectively, for screening all women and
for non-Western migrants only. A decline of treatment costs to
J3,500 and J6,000 respectively will be cost-effective at a cost-
effective threshold of J20,000.
In scenario 3, in which all women with genotype 1–4 would be
on the new improved treatment regimen, HCV screening was not
cost-effective with an ICER of J88,162. The same was true for
non-Western women with an ICER of J86.005. Best-case
Table 3. Best-case scenarios for screening all pregnant women (scenario 1a) and first-generation non-Western women (scenario
1b).
Mean costs Mean life years Incremental costs LYG ICER (J/LYG)
All pregnant women Screening J 41,809 35492.8 J 30,228 1,55 J 19,505
No routine screening J 11,581 35491.3
non-Western migrants Screening J 78,978 36378.6 J 55.320 3,16 J 17,533
No routine screening J 23,658 36375.4
With parameter optimization 625% and incremental cost-effectiveness ratio calculated with reference to the ‘‘no routine screening’’ strategy.
LYG:life years gained.
ICER: incremental cost-effectiveness ratio.
doi:10.1371/journal.pone.0070319.t003
Figure 2. Cost-effectiveness acceptability curves (CEAC) for all pregnant women (indicated with the black line) and for first-
generation non-Western women (indicated with the grey line) for scenarios 1a and 1b. The graph shows the probability of screening
being cost-effective when different cost-effectiveness thresholds are used, resulting from uncertainty analysis. In the Netherlands, the certain cost-
effective threshold is J20,000 (indicated by the dotted line) and regimens that are calculated at J20,000 and J50,000 are potentially cost-effective.
As shown in both scenarios, 10% of the simulations were below the cost-effectiveness threshold of J20 000.
doi:10.1371/journal.pone.0070319.g002
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scenarios revealed ICERs of J 42,270, and J 32,853, respectively,
for screening all women and for screening non-Western migrants
only. A decline of treatment costs to J4,250 and J7,250
respectively will conform to the cost-effective threshold of
J20,000.
Sensitivity analysis
The cost-effectiveness acceptability curves (CEACs) derived
from the sensitivity analysis are given in Figure 2, which shows that
screening all pregnant women is probably not cost-effective.
However, screening only first-generation non-Western migrants is
probably cost-effective.
The one-way sensitivity analysis showed that the ICER for
screening all pregnant women is most sensitive to changes in the
transition probabilities to cirrhosis, as shown in the tornado
diagram in Figure 3a. Other parameters that have a large impact
on the outcome are the treatment costs, successful treatment
outcome, the prevalence of HCV, the costs of HCV testing, the
transition from cirrhosis to decompensated cirrhosis, and the
probability from chronic HCV infection to treatment. The
sensitivity analysis for first generation non-Western women
showed also that the ICER for screening only this specific group
of women is most sensitive to changes in the probability rates of
transition to to cirrhosis (see Figure 3b). Other parameters that
have a large impact on the outcome are the same as discussed
above.
In addition we performed our analysis with different discount
rates. If a discount rate 0% for both costs and life years was used
the ICER for respectively all pregnant women and first generation
non-Western women was J10,745 and J7,099. Discounting at
3% we found an ICER of respectively J98,637 and J90,818 and
discounting at 4% we found an ICER of respectively J 166,494
and J157,633..
Discussion
In this study, we found that screening all pregnant women in
Amsterdam for HCV within the existing screening program for
other infections during pregnancy is probably not cost-effective.
Screening first-generation non-Western women was moderately
cost-effective. These findings are partly due to the slow progression
of HCV infection to cirrhosis, especially for women [18], and the
relatively high costs for patients treated with new protease
inhibitors (boceprevir and telaprevir). However, standard of care
treatment is estimated in the literature to be cost-effective in
treatment-naı¨ve patients [19]. Therefore we also estimated the
ICER when standard of care treatment is used (scenarios 2a and
2b) and found a more favourable ICER than when new treatment
options are used, but still above the certain cost-effective threshold
of J20,000. Other studies found that HCV screening in relatively
low-prevalence or low-risk populations is not cost-effective [12,20].
One study indicated that screening in a migrant population is only
cost-effective if the HCV prevalence is at least 2% [21]. Initially,
we assumed that when HCV screening is integrated into an
existing screening program it may be cost-effective, since
expenditures for extending an already existing screening are low
and the only costs are for testing.
Figure 3. Tornado diagrams of the sensitivity analyses. Diagram A) describes scenario 1a and diagram B) scenario describes scenario 1b. Both
diagrams show the change in ICER when reducing or increasing each parameter with 25%.
doi:10.1371/journal.pone.0070319.g003
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Notably, the low prevalence found in our study population -
which means that high numbers are required for screening detect
one infected person- was another reason for the slightly
unfavourable cost-effectiveness in all pregnant women.
The best-case analyses show the potential for an ICER below
the threshold of J20,000 per life-year gained. In a separate
analysis, we also found a favourable cost-effectiveness for the
standard of care treatment (scenarios 2a and 2b). However, we did
not find a favourable cost-effectiveness in the best-case analysis of
scenario 3a and 3b, where all women, independent of the
genotype, were on the new treatment regimen. The high cost of
the new hypothetical future treatment regime obviously influenced
the cost-effectiveness outcome negatively.
We included new treatment options for genotype 1, which were
licensed in 2012. Although treatment outcomes have improved
with these new medications, costs are still high because of patents
on the medications. We estimated that if treatment costs decline to
J3,750 per treatment, screening pregnant women will be cost-
effective. Unfortunately, it is unlikely that any decrease in costs of
the newly approved drugs will be large enough (this involves a
reduction in price of J31,000) to result in favourable cost-
effectiveness in the upcoming years. However, potent treatment
options, without peginterferon, are expected to be available with
shorter treatment durations, fewer side-effects [22] and with more
favourable costs in the future. The probability of receiving
treatment will increase as well, because of the better treatment
options and thus result in a more favourable cost-effectiveness
ICER.
In addition, we might have overestimated the duration and the
costs of treatment and underestimated the ICER because in
practice women can receive a shortened treatment because they
have achieved a rapid virological response in the early phase of
treatment.
In this study only direct medical costs and benefits are included;
indirect costs were not considered. Since side effect could be very
severe this could influence the outcome negatively. Some costs
were derived from literature [23], and converted to 2011 index
prices. Also, we only measured life-years and did not take other
health outcomes into account, which means that a life-year spent
with diseases contributes as much to the ICER as a healthy life-
year. Using health-related quality of life next to life-years would
probably give a more cost-effective outcome, because screening
may detect HCV-infected women years earlier and thus prevent
years of discomfort and severe complications in a later stage of life.
However, women can also experience a small loss of quality of life
because of early detection during their pregnancy. Treatment is a
contraindication during pregnancy and the small chance of
mother-to-child transmission can therefore not be averted which
could give the mother stress. Nevertheless, we believe that more
quality is gained than lost by early detection. In order to test our
assumptions, quality of life will be included in our model in a
following study on pregnancy and HCV.
We ignored the costs of health care and screening in the child
because the transmission rate from mother to child is relatively low
at 5% (depending on the RNA load of the mother); also, the
prevalence in mothers is low [8], and therefore the costs related to
the mother and her infection vastly outweighs the small costs for
the children. Taking the benefits for the child into account possibly
has a small effect on the ICER. When the mother is diagnosed
with HCV, the child can be closely monitored for possible
transmission with HCV and start treatment when indicated.
Unfortunately, there are limited options to prevent mother-to-
child transmission, since the precise transmission route from
mother to child is unknown, most likely transmission occurs during
birth [8]. Treatment of pregnant women is not indicated and
cannot prevent transmission to the child, because neither birth by
caesarean section nor lack of breastfeeding lower the transmission
rate significantly [8]. Because of the transmission rate, HCV
screening during pregnancy is probably not cost-effective for the
child either.
Although implementing HCV screening during pregnancy in an
existing routine screening program for infectious diseases with the
currently available treatment regimen may not be cost-effective for
all pregnant women, the ICER for first-generation non-Western
women shows a modest cost-effectiveness outcome. In line with
other studies [11], our results suggest that risk based screening
could be cost-effective in low prevalence counties like the
Netherlands. Since first-generation non-Western migrants com-
prise a large proportion of the undiagnosed HCV-infected
population in the Netherlands, this risk group should be targeted
for screening [3]. This, together with the high screening uptake of
99.8% [24] in the existing routine should argue for implementa-
tion of HCV screening for first-generation non-Western women.
In addition, the best-case analysis shows potential for an ICER
below the J20,000 per LYG. Furthermore, more improved
treatment outcomes, without peginterferon and with shorter
treatment duration, are expected in the coming years, which are
likely to enhance cost-effectiveness even more.
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